Skip to Content

Sankar N. Maity, PhD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, The University of Texas Graduate School of Biomedical Science, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1374
Houston, TX 77030
Room Number: B3.4847

Education & Training

Degree-Granting Education

1992 The University of Texas MD Anderson Cancer Center, Houston, TX, UCF Fellowship, Molecular Genetics
1991 University of Calcutta, Calcutta, India, PHD, Biochemistry
1991 The University of Texas MD Anderson Cancer Center, Houston, TX, Postdoctoral, Molecular Genetics
1980 University of Calcutta, Calcutta, India, MS, Biochemistry

Postgraduate Training

1/1987-1991 Postdoctoral Research Fellow, Department of Molecular Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX
1982-1987 Post Graduate, Bose Institute, Calcutta, India


Academic Appointments

Associate Professor, Department of Molecular Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2001-8/2008
Assistant Professor, Department of Molecular Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/1992-8/2001
Instructor, Department of Molecular Genetics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/1991-8/1992

Institutional Committee Activities

Member, Review Committee for Institutional Research Grant, 2005-2008
Member, Institutional Animal Care and Use Committee, 2001-2003
Member, Review Committee for Institutional Research Grant, 2001-2003
Member, Graduate School of Biomedical Sciences Committee, 1996-present

Honors and Awards

1992 Hulda Irene Duggan Arthritis Investigator Award
1992 University Cancer Foundation Basic Science Fellow

Selected Publications

Peer-Reviewed Original Research Articles

1. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 3/2016. e-Pub 11/2015. PMCID: PMC4794379.
2. Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics. e-Pub 2/2016. PMID: 26890396.
3. Paranjape AN, Soundararajan R, Werden SJ, Joseph R, Taube JH, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba I, Miura N, Dhillon J, Mahajan N, Mahajan K, Chang JT, Ittmann M, Maity SN, Logothetis C, Tang DG, Mani SA. Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene. e-Pub 1/2016. PMID: 26804168.
4. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22(1):107-21, 1/2016. e-Pub 8/2015. PMCID: PMC4703437.
5. Shi Z, Chiang CI, Labhart P, Zhao Y, Yang J, Mistretta TA, Henning SJ, Maity SN, Mori-Akiyama Y. Context-specific role of SOX9 in NF-Y mediated gene regulation in colorectal cancer cells. Nucleic Acids Res 43(13):6257-69, 7/2015. e-Pub 6/2015. PMCID: PMC4513854.
6. Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics 14(3):471-83, 3/2015. e-Pub 12/2014. PMCID: PMC4349970.
7. Mitani Y, Rao PH, Maity SN, Lee YC, Ferrarotto R, Post JC, Licitra L, Lippman SM, Kies MS, Weber RS, Caulin C, Lin SH, El-Naggar AK. Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma (SDC) of Both Sexes: Potential Therapeutic Ramifications. Clin Cancer Res 20(24):6570-81, 12/2014. e-Pub 10/2014. PMCID: PMC4268116.
8. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Sci Signal 7(326):ra47, 5/2014. e-Pub 5/2014. PMCID: PMC4135429.
9. Yamanaka T, Tosaki A, Kurosawa M, Matsumoto G, Koike M, Uchiyama Y, Maity SN, Shimogori T, Hattori N, Nukina N. NF-Y inactivation causes atypical neurodegeneration characterized by ubiquitin and p62 accumulation and endoplasmic reticulum disorganization. Nat Commun 5:3354, 2014. e-Pub 2/2014. PMID: 24566496.
10. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular Classification of Prostate Cancer Progression: foundation for Marker-Driven Treatment of Prostate Cancer. Cancer Discov 3(8):849-61, 8/2013. e-Pub 6/2013. PMCID: PMC3926428.
11. Efstathiou E, Karlou M, Wen S, Hoang A, Pettaway CA, Pisters LL, Maity S, Troncoso P, Logothetis CJ. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 73(2):153-61, 1/2013. e-Pub 7/2012. PMCID: PMC3878994.
12. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate 72(15):1638-47, 11/2012. e-Pub 3/2012. PMID: 22457212.
13. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of B-Catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 18(3):726-36, 2/2012. PMCID: PMC3271798.
14. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features. Clin Cancer Res 18(3):666-77, 2/2012. e-Pub 12/2011. PMCID: PMC3923417.
15. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways. PLoS One 7(12):e51189, e51189. doi: 10.1371/journal.pone.0051189. Epub 2012 Dec 26., 2012. e-Pub 12/2012. PMCID: PMC3530555.
16. Aparicio A, Logothetis CJ, Maity SN. Understanding the Lethal Variant of Prostate Cancer: Power of Examining Extremes. Cancer Discov 1(6):466–68, 11/2011. PMCID: PMC4133693.
17. Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. BMP4 Promotes Prostate Tumor Growth in Bone Through Osteogenesis. Cancer Res 71(15):5194-203, 8/2011. e-Pub 6/2011. PMCID: PMC3148283.
18. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 6/2011. e-Pub 11/2010. PMCID: PMC3883511.
19. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5a-reductase isoenzymes in prostate cancer: Implications for prostate cancer prevention. PLoS One 6(12):28840, 2011. e-Pub 12/2011. PMCID: PMC3237548.
20. Luo R, Klumpp SA, Finegold MJ, Maity SN. Inactivation of CBF/NF-Y in postnatal liver causes hepatocellular degeneration, lipid deposition, and endoplasmic reticulum stress. Sci Rep 1(136):1-7, 2011. e-Pub 11/2011. PMCID: PMC3216617.
21. Coustry F, Oh CD, Hattori T, Maity SN, de Crombrugghe B, Yasuda H. The dimerization domain of SOX9 is required for transcription activation of a chondrocyte-specific chromatin DNA template. Nucleic Acids Res 38(18):6018-28, 10/2010. e-Pub 5/2010. PMCID: PMC2952863.
22. Oh CD, Maity SN, Lu JF, Zhang J, Liang S, Coustry F, de Crombrugghe B, Yasuda H. Identification of SOX9 interaction sites in the genome of chondrocytes. PLoS One 5(4):E10113, doi:10.1371/journal.pone.0010113, 2010. e-Pub 4/2010. PMCID: PMC2852419.
23. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 10(10):599, 2010. e-Pub 11/2010. PMCID: PMC2988752.
24. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 8/2008. PMCID: PMC2447924.
25. Luo R, Lu JF, Hu Q, Maity SN. CBF/NF-Y controls endoplasmic reticulum stress induced transcription through recruitment of both ATF6 (N) and TBF. J Cell Biochem 104(5):1708-23, 8/2008. PMID: 18348279.
26. Hu Q, Lu JF, Luo R, Sen S, Maity SN. Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res 34(21):6272-85, 2006. e-Pub 11/2006. PMCID: PMC1693888.
27. Chattopadhyay C, Hawke D, Kobayashi R, Maity SN. Human p32, interacts with B subunit of the CCAAT-binding factor, CBF/NF-Y, and inhibits CBF-mediated transcription activation in vitro. Nucleic Acids Res 32(12):3632-41, 2004. e-Pub 7/2004. PMCID: PMC484179.
28. Bhattacharya A, Deng JM, Zhang Z, Behringer R, de Crombrugghe B, Maity SN. The B subunit of the CCAAT box binding transcription factor complex (CBF/NF-Y) is essential for early mouse development and cell proliferation. Cancer Res 63(23):8167-72, 12/2003. PMID: 14678971.
29. Hu Q, Bhattacharya C, Maity SN. CCAAT binding factor (CBF) binding mediates cell cycle activation of topoisomerase IIalpha. Conventional CBF activation domains are not required. J Biol Chem 277(40):37191-200, 10/2002. e-Pub 7/2002. PMID: 12149265.
30. Li X, Bhattacharya C, Dayal S, Maity S, Klein WH. Ectoderm gene activation in sea embryos mediated by the CCAAT-binding factor. Differentiation 70(2-3):109-19, 5/2002. PMID: 12076338.
31. Coustry F, Hu Q, de Crombrugghe B, Maity SN. CBF/NF-Y functions both in nucleosomal disruption and transcription activation of the chromatin-assembled topoisomerase IIalpha promoter. Transcription activation by CBF/NF-Y in chromatin is dependent on the promoter structure. J Biol Chem 276(44):40621-30, 11/2001. PMID: 11514576.
32. Zhu XS, Linhoff MW, Li G, Chin KC, Maity SN, Ting JP. Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter. Mol Cell Biol 20(16):6051-61, 8/2000. PMCID: PMC86081.
33. Hu Q, Maity SN. Stable expression of a dominant negative mutant of CCAAT binding factor/NF-Y in mouse fibroblast cells resulting in retardation of cell growth and inhibition of transcription of various cellular genes. J Biol Chem 275(6):4435-44, 2/2000. PMID: 10660616.
34. Faniello MC, Bevilacqua MA, Condorelli G, de Crombrugghe B, Maity SN, Avvedimento VE, Cimino F, Costanzo F. The B subunit of the CAAT-binding factor NFY binds the central segment of the Co-activator p300. J Biol Chem 274(12):7623-6, 3/1999. PMID: 10075648.
35. Liang SG, Maity SN. Pathway of complex formation between DNA and three subunits of CBF/NF-Y. Photocross-linking analysis of DNA-protein interaction and characterization of equilibrium steps of subunit interaction and DNA binding. J Biol Chem 273(47):31590-8, 11/1998. PMID: 9813075.
36. Maity SN, de Crombrugghe B. Role of the CCAAT-binding protein CBF/NF-Y in transcription. Trends Biochem Sci 23(5):174-8, 5/1998. PMID: 9612081.
37. Coustry F, Sinha S, Maity SN, Crombrugghe B. The two activation domains of the CCAAT-binding factor CBF interact with the dTAFII110 component of the Drosophila TFIID complex. Biochem J 331 ( Pt 1):291-7, 4/1998. PMCID: PMC1219351.
38. Bi W, Wu L, Coustry F, de Crombrugghe B, Maity SN. DNA binding specificity of the CCAAT-binding factor CBF/NF-Y. J Biol Chem 272(42):26562-72, 10/1997. PMID: 9334236.
39. Chen SS, Ruteshouser EC, Maity SN, de Crombrugghe B. Cell-specific in vivo DNA-protein interactions at the proximal promoters of the pro alpha 1(I) and the pro alpha2(I) collagen genes. Nucleic Acids Res 25(16):3261-8, 8/1997. PMCID: PMC146878.
40. Das H, Maity SN, Chowdhury S, Chatterjee D. Consecutive five abortions in a case of septate uterus--ended in a term pregnancy following modified Jones' metroplasty operation. J Indian Med Assoc 95(1):23, 1/1997. PMID: 9212567.
41. Sinha S, Maity SN, Seldin MF, de Crombrugghe B. Chromosomal assignment and tissue expression of CBF-C/NFY-C, the third subunit of the mammalian CCAAT-binding factor. Genomics 37(2):260-3, 10/1996. PMID: 8921405.
42. Lefebvre V, Zhou G, Mukhopadhyay K, Smith CN, Zhang Z, Eberspaecher H, Zhou X, Sinha S, Maity SN, de Crombrugghe B. An 18-base-pair sequence in the mouse proalpha1(II) collagen gene is sufficient for expression in cartilage and binds nuclear proteins that are selectively expressed in chondrocytes. Mol Cell Biol 16(8):4512-23, 8/1996. PMCID: PMC231450.
43. Kim IS, Sinha S, de Crombrugghe B, Maity SN. Determination of functional domains in the C subunit of the CCAAT-binding factor (CBF) necessary for formation of a CBF-DNA complex: CBF-B interacts simultaneously with both the CBF-A and CBF-C subunits to form a heterotrimeric CBF molecule. Mol Cell Biol 16(8):4003-13, 8/1996. PMCID: PMC231396.
44. Hasegawa T, Zhou X, Garrett LA, Ruteshouser EC, Maity SN, de Crombrugghe B. Evidence for three major transcription activation elements in the proximal mouse proalpha2(I) collagen promoter. Nucleic Acids Res 24(16):3253-60, 8/1996. PMCID: PMC146084.
45. Coustry F, Maity SN, Sinha S, de Crombrugghe B. The transcriptional activity of the CCAAT-binding factor CBF is mediated by two distinct activation domains, one in the CBF-B subunit and the other in the CBF-C subunit. J Biol Chem 271(24):14485-91, 6/1996. PMID: 8662945.
46. Maity SN, de Crombrugghe B. Purification, characterization, and role of CCAAT-binding factor in transcription. Methods Enzymol 273:217-32, 1996. PMID: 8791615.
47. Sinha S, Kim IS, Sohn KY, de Crombrugghe B, Maity SN. Three classes of mutations in the A subunit of the CCAAT-binding factor CBF delineate functional domains involved in the three-step assembly of the CBF-DNA complex. Mol Cell Biol 16(1):328-37, 1996. PMCID: PMC231007.
48. Sinha S, Maity SN, Lu J, de Crombrugghe B. Recombinant rat CBF-C, the third subunit of CBF/NFY, allows formation of a protein-DNA complex with CBF-A and CBF-B and with yeast HAP2 and HAP3. Proc Natl Acad Sci U S A 92(5):1624-8, 2/1995. PMCID: PMC42572.
49. Coustry F, Maity SN, de Crombrugghe B. Studies on transcription activation by the multimeric CCAAT-binding factor CBF. J Biol Chem 270(1):468-75, 1/1995. PMID: 7814413.
50. Sohn KY, Maity SN, de Crombrugghe B. Studies on the structure of the mouse CBF-A gene and properties of a truncated CBF-A isoform generated from an alternatively spliced RNA. Gene 139(2):147-53, 2/1994. PMID: 7509302.
51. Goldberg H, Helaakoski T, Garrett LA, Karsenty G, Pellegrino A, Lozano G, Maity S, de Crombrugghe B. Tissue-specific expression of the mouse alpha 2(I) collagen promoter. Studies in transgenic mice and in tissue culture cells. J Biol Chem 267(27):19622-30, 9/1992. PMID: 1527081.
52. Maity SN, Sinha S, Ruteshouser EC, de Crombrugghe B. Three different polypeptides are necessary for DNA binding of the mammalian heteromeric CCAAT binding factor. J Biol Chem 267(23):16574-80, 8/1992. PMID: 1644837.
53. Maity SN, de Crombrugghe B. Biochemical analysis of the B subunit of the heteromeric CCAAT-binding factor. A DNA-binding domain and a subunit interaction domain are specified by two separate segments. J Biol Chem 267(12):8286-92, 4/1992. PMID: 1569083.
54. Vuorio T, Maity SN, de Crombrugghe B. Purification and molecular cloning of the "A" chain of a rat heteromeric CCAAT-binding protein. Sequence identity with the yeast HAP3 transcription factor. J Biol Chem 265(36):22480-6, 12/1990. PMID: 2266139.
55. Maity SN, Vuorio T, de Crombrugghe B. The B subunit of a rat heteromeric CCAAT-binding transcription factor shows a striking sequence identity with the yeast Hap2 transcription factor. Proc Natl Acad Sci U S A 87(14):5378-82, 7/1990. PMCID: PMC54327.
56. Maity SN, Ray K, Banerjee A, Mukhopadhyay K, Roychowdhury S, Chaudhuri GG, Biswas BB, Bhattacharyya B. Role of B-ring of colchicine in its binding to tubulin. Indian J Biochem Biophys 25(6):585-9, 12/1988. PMID: 3255673.
57. Maity SN, Golumbek PT, Karsenty G, de Crombrugghe B. Selective activation of transcription by a novel CCAAT binding factor. Science 241(4865):582-5, 7/1988. PMID: 3399893.
58. Maity SN, Bhattacharyya B. Properties of B-ring analogues of colchicine. FEBS Lett 218(1):102-6, 6/1987. PMID: 3595855.
59. Banerjee A, Maity SN, Raychaudhuri S, Bhattacharyya B. Role of B-ring of colchicine in its binding to zinc (II)-induced tubulin sheets. J. Biosci 11:525-536, 1987.
60. Bhattacharyya B, Howard R, Maity SN, Brossi A, Sharma PN, Wolff J. B-ring regulation of colchicine binding kinetics and fluorescence. Proc Natl Acad Sci U S A 83(7):2052-5, 4/1986. PMCID: PMC323228.
61. Choudhury G, Maity SN, Bhattacharyya B, Biswas BB. B-ring of colchicine and its role in taxol induced tubulin polymerization. FEBS Lett 197(1-2):31-4, 3/1986. PMID: 2868923.

Invited Articles

1. Ruteshouse EC, Maity SN, de Crombrugghe B. In vitro transcription assay for eucaryotic gene expression. Methods in Nucleic Acids Research:321-333, 1991.
2. De Crombrugghe B, Vuorio T, Karsenty G, Maity SN, Rutheshouse EC, Goldberg H. Transcriptional mechanisms for the expression of type I collagen genes. Annals of the Rheumatic Diseases 50:872-876, 1991.
3. De Crombrugghe B, Karsenty G, Maity SN, Vuorio T, Rossi P, Ruteshouse EC, McKinney SH, Lozano G. Transcriptional mechanisms controlling types I and III collagen genes. Annals of New York Academy of Sciences 580:88-96, 1990.
4. Bhattacharyya B, Ghosh CG, Maity SN, Biswas BB. The role of the B-ring of colchicine on taxol induced polymerization. Ann N Y Acad Sci 466:791-793, 1986. PMID: 2873782.


1. Sankar N. Maity, Guanglin Wu, Jing-Fang Lu, Anh Hoang, Yosef Landesman, Dilara McCauley, Robert Carlson, Tami Rashal, Sharon Shacham, Bradley McIntosh Broom, Keith A. Baggerly, Ana Aparicio, Eleni Efstathiou, John C. Araujo and Christopher Logothetis. Effect of Selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppresors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth. 2015 Genitourinary Cancers Symposium 33(No 7_suppl (March 1 Supplement)):2015:277 (#277), 2/2015. e-Pub 2/2015.
2. Maity SN, Titus, M, Wu G, Lu J-F, Ramachandran S, Eisner JR, Hoekstra WJ, Schotzinger RJ, Moore WR, Logothetis CJ, Araujo JC, Efstathiou. Effect Of A Selective CYP17-lyase Inhibitor, VT-464, On Androgen Receptor Signaling in Prostate Cancer Cells And On Tumor Growth Of A Patient-derived Castrate-Resistant Prostate Cancer Xenograft. AACR Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research (#23558_1), 1/2014.
3. Maity SN, Wu G, Lu J, Hoang A, Landesman Y, McCauley D, Schacham S, Kauffman M, Aparicio A, Efstathiou E, Araujo J, Logothetis. Preclinical Efficacy of the Novel, Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) on Castration Resistant Prostate Cancer. AACR Annual Conference, 1/2014.
4. Aparicio A, Maity SN, Wang X, Hoang A, Efstathiou E, Troncoso P, Logothetis C. Amolecular characterization of the anaplastic prostate carcinomas. AACR 2013 Annual Conference, 4/2013.
5. Maity SN, Titus M, Wu G, Lu J-F, Ramachandran S, Eisner JR, Rafferty SW, Schotzinger RJ, Moore WR, Logothetis CJ, Araujo JC, Efstathiou E. Efficacy of VT-464, a Novel Selective Inhibitor of Cytochrome P450 17,20 lyase, in Castrate-Resistant Prostate Cancer. AACR 2013 Annual Conference, 4/2013.
6. Lin S; Maity SN. BMP4 promotes prostate tumor growth in bone through osteogenesis. CPRIT Innovations in Cancer Prevention and Research Conference:61, 11/2011.
7. Tzeelpi V, Maity SN, Zhang J, Liang S, Lu JF, Anh H, Kleb B, Efstathiou E, Navone N, Troncosco P, Logothetis C, Aparicio A. Molecular profiling of prostate cancer xenografts and human specimens reveals overexpression of UBE2C/UBCH10 and activation of aurora kinases in poorly differentiated neuroendocrine carcinoma of the prostate. Cancer Research 78(8), 4/2011.
8. Wan X, Liu J, Lu JF, Tzelep V, Yang J, Starbuck M, Wang J, Efstathiou E, Vazquez ES, Troncosco P, Maity SN, Navone N. Beta-catenin-TCF pathway and castrate resistant progression of osteoblastic bone metastases. IMPaCT Conference, 3/2011.
9. Wan X, Yang J, Starbuck MW, Ravoori MK, Lu JF, Kundra V, Maity SN, Wan F, Navone NM. Targeting fiboblast growth factor signaling in prostate cancer. 2010 Scientific Retreat and Rolanette and Berdon Lawrence Research Award Competition, Baylor College of Medicine, The Bone Disease Program of Texas, 4/2010.
10. Wan X, Yang J, Starbuck MW, Ravoori MK, Lu JF, Kundra V, Maity SN, Wang F, Navone NM. Targeting fibroblast growth factor signaling in prostate cancer. AACR 101st Annual Meeting, 2010.
11. Karlou MS, Yang J, Maity SN, Navone NM, Lu JF, Wan X, Hoang A, Logothetis CJ, Efstathiou E. Preclinical model selection for the study of hedgehog signaling in androgen resistant/independent growth in prostate cancer from bedside to bench. 5th International Conference on Tumor Microenvironment: progression, Therapy & Prevention (Poster Presentation), 10/2009.

Grant & Contract Support

Title: From Prognostication to Prediction: A Comprehensive Characterization of Murine and Clinical m-CRPC from “Microenvironment Dependence” to Aggressive Variants
Funding Source: Prostate Cancer Foundation - Clinical Challenge
Role: Associate Professor
Principal Investigator: Logothetis and Gallick (MPI)
Duration: 10/1/2014 - 9/30/2016
Title: Androgen Deprivation Therapy Resistance in Castrate Resistant Prostate Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2014 - 3/31/2016
Title: MDA Prostate cancer tumor graft models linking molecular signaling signature to clinical stage
Funding Source: Prostate Cancer Research Program (PCRP)
Role: Principal Investigator
Duration: 1/1/2014 - 12/31/2016
Title: Endothelial-to-osteoblast transition in prostate cancer bone metastasis
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Lin
Duration: 4/1/2013 - 3/31/2018
Title: Co-clinical study to determine efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20 lyase, in castrate-resistant prostate cancer
Funding Source: Viamet
Role: Principal Investigator
Duration: 2/25/2013 - 2/26/2016
Title: Mechanisms of Resistance to Androgen Biosynthesis Inhibition in Castrate-Resistant Prostate Cancer Bone Metastases
Funding Source: Prostate Cancer Foundation Challenge Grant
Role: Co-Investigator
Principal Investigator: Christopher Logothetis
Duration: 6/1/2011 - 5/31/2013
Title: Project 4 - Targeting FGF Signaling in Prostate Cancer Progression
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Christopher Logothetis
Duration: 9/2/2009 - 8/31/2014
Title: Beta-Catenin/TCF Pathway and Castrate-Resistant Progression of Osteoblastic Bone Metastases
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Nora Navone
Duration: 5/12/2008 - 6/30/2012
Title: Control of Chondrocyte Differentiation
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: B. de Crombrugghe
Duration: 9/20/2006 - 7/31/2011
Title: Function of CBF during progression of G2/M phase of cell cycle
Funding Source: Institutional Research Grant Program, MD Anderson Cancer Center
Role: Principal Investigator
Duration: 7/2005 - 8/2007
Title: Role of CBF during skin tumor development
Funding Source: University Cancer Foundation
Role: Principal Investigator
Duration: 5/2005 - 8/2007
Title: Role of CBF/NF-Y in Transcription: type I collagen genes
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/2000 - 5/2006
Title: Role of CBF/NF-Y in Transcription: Type I collagen genes
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 6/1995 - 5/2000
Title: Regulation of type 1 collagen genes expression
Funding Source: University Cancer Foundation
Role: Principal Investigator
Duration: 9/1992 - 8/1993
Title: Regulation of type 1 collagen by recombinant transcription factor
Funding Source: Arthritis Foundation - Arthritis Investigator Award
Role: Principal Investigator
Duration: 7/1992 - 6/1995

Last updated: 4/5/2016